Innoviva (INVA) Common Equity (2010 - 2026)
Innoviva's (INVA) quarterly Common Equity came in at $1.3 billion in Q1 2026, up 107.4% YoY from $646.9 million in Q1 2025, and up 14.39% on a QoQ basis from $1.2 billion in Q4 2025.
Analysis
Innoviva (INVA) Common Equity (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Common Equity rose 107.4% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 107.4% YoY) and the FY2025 annual result came in at $1.2 billion, up 69.69% from the prior year.
- Common Equity rose to $1.3 billion in Q1 2026, from $1.2 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $552.2 million in Q1 2022.
- A 5-year average of $727.0 million and a median of $665.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity fell 20.74% — and 2026, when it soared 107.4%.
- Tracing INVA's Common Equity over 5 years: stood at $565.8 million in 2022, then advanced by 19.29% to $675.0 million in 2023, then rose by 2.4% to $691.2 million in 2024, then surged by 69.69% to $1.2 billion in 2025, then advanced by 14.39% to $1.3 billion in 2026.
- The last three Common Equity figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 1.23 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Bn |
| Mar 31, 2026 | 1.34 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 714.82 Mn |
| Mar 31, 2025 | 646.91 Mn |
| Dec 31, 2024 | 691.16 Mn |
| Sep 30, 2024 | 668.54 Mn |
| Jun 30, 2024 | 665.52 Mn |
| Mar 31, 2024 | 703.68 Mn |
| Dec 31, 2023 | 674.96 Mn |
| Sep 30, 2023 | 627.49 Mn |
| Jun 30, 2023 | 555.09 Mn |
| Mar 31, 2023 | 561.49 Mn |
| Dec 31, 2022 | 565.79 Mn |
| Sep 30, 2022 | 641.37 Mn |
| Jun 30, 2022 | 565.46 Mn |
| Mar 31, 2022 | 552.22 Mn |
| Dec 31, 2021 | 525.94 Mn |
| Sep 30, 2021 | 491.81 Mn |